DEF: Herbalife Sets 2026 AGM, Details Executive Pay & Governance

Herbalife Ltd. announces its 2026 Annual General Meeting of Shareholders, outlining proposals for director elections, executive compensation, and auditor ratification, alongside a review of 2025 financial performance and strategic initiatives.

Summary

• The 2026 Annual General Meeting of Shareholders will be held on Thursday, April 30, 2026, at 8:30 a.m. Pacific Daylight Time, at 800 W. Olympic Blvd., Suite 406, Los Angeles, CA 90015, with a live listen-only audio webcast also available.
• Shareholders of record as of March 9, 2026, are entitled to notice of and to vote at the meeting.
• Key proposals include the election of 11 director nominees (including new nominee Des Walsh), an advisory vote to approve named executive officer compensation, and an advisory ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
• The company reported FY 2025 net sales of $5.0 billion, representing a 0.9% increase versus 2024, or 2.5% on a constant currency basis.
• Herbalife achieved its second consecutive year of adjusted EBITDA growth and adjusted EBITDA margin expansion in 2025.
• Debt was reduced by approximately $283 million in 2025, bringing the total leverage ratio down to 2.8x at December 31, 2025.
• New distributors joining Herbalife worldwide increased 2% year-over-year in 2025 and 13% on a two-year stacked basis.
• Strategic acquisitions in April 2025 included assets of Pro2col Health LLC (digital health platform), a 51% ownership interest in HBL Link Bioscience LLC (precision nutrition), and assets of Pruvit Ventures, Inc. (ketone supplements).
• Global sports icon Cristiano Ronaldo invested $7.5 million and provided sponsorship rights for a 10% equity stake in HBL Pro2col Software, LLC in February 2026.
• The 2025 executive compensation program reintroduced Performance Share Units (PSUs) as 50% of long-term incentives, implemented Restricted Cash Units (RCUs) for 25%, and refined Short-Term Incentive (STI) metrics to 50% Local Currency Net Sales and 50% Adjusted EBITDA.
• For the 2025 annual incentive plan, actual Adjusted EBITDA of $634.869 million exceeded the target of $620 million (102.4% achievement), while Local Currency Net Sales of $4,920.157 million achieved 99.0% of the $4,967.793 million target, resulting in a total payout of 109.5%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the reported financial improvements, strategic acquisitions, and significant external investment, which collectively indicate a strengthening business and clear growth trajectory. The proactive adjustments to executive compensation based on shareholder feedback also reflect good governance.

Positives

• FY 2025 net sales increased by 0.9% year-over-year to $5.0 billion, or 2.5% on a constant currency basis, demonstrating underlying business growth.
• Achieved the second consecutive year of adjusted EBITDA growth and adjusted EBITDA margin expansion, indicating improved profitability.
• Reduced debt by approximately $283 million in 2025, lowering the total leverage ratio to 2.8x at December 31, 2025, strengthening the financial foundation.
• New distributors worldwide increased 2% year-over-year and 13% on a two-year stacked basis, reflecting sustained, multi-year momentum in the core business.
• Completed strategic acquisitions of Pro2col Health LLC, HBL Link Bioscience LLC, and Pruvit Ventures, Inc., expanding digital health, precision nutrition, and product offerings.
• Secured a significant investment from global sports icon Cristiano Ronaldo in HBL Pro2col Software, LLC, providing $7.5 million and sponsorship rights for a 10% equity stake.
• Executive compensation program for 2025 was enhanced by reintroducing PSUs (50% of LTI) and implementing RCUs (25% of LTI), aligning pay with long-term performance and moderating equity dilution.
• Actual Adjusted EBITDA of $634.869 million exceeded the target of $620 million for the 2025 annual incentive plan, leading to a 124.0% payout for that metric.
• The total payout achieved for the 2025 annual incentive plan was 109.5%, reflecting strong overall performance against targets.
• Opened a new, state-of-the-art Center of Excellence in Torrance, California, housing Quality Control, R&D, and Sensory Evaluation laboratories, enhancing product development capabilities.
• Corporate governance highlights include annual director elections, an independent lead director, majority voting standard for uncontested elections, and a Sustainability Committee providing direct board oversight of environmental and social sustainability.
• The Herbalife Family Foundation awarded approximately $5 million in grants to 165 nonprofit organizations across 60 countries and territories in 2025, demonstrating strong community and social impact.

Negatives

• The 2025 Adjusted EBITDA target of $620 million was below the 2024 Adjusted EBITDA of $645.8 million, reflecting anticipated foreign currency headwinds.
• Local Currency Net Sales for 2025 ($4,920.157 million) slightly missed the target ($4,967.793 million), achieving 99.0% of the target.
• The shareholder advisory vote on executive compensation in 2025 received only approximately 51.5% of votes cast in favor, indicating a need for continued attention to shareholder feedback.
• Des Walsh, a new director nominee, was not determined independent due to receiving more than $120,000 in direct compensation from the Company within the last three years.
• Directors Rodica Macadrai and Juan Miguel Mendoza are not considered independent because they receive income as top distributors of Herbalife products.
• Michael O. Johnson's base salary was reduced from $1,280,000 to $740,742 in connection with his transition to Executive Chairman, which could be perceived as a negative for his personal compensation.

Risks

• Forward-looking statements are inherently uncertain, and actual results or outcomes could differ materially for a variety of reasons, as described in the 2025 Annual Report on Form 10-K.
• Historical, current, and forward-looking sustainability-related statements may be based on developing standards, evolving internal controls, and assumptions subject to future change.
• The Board delegates specific enterprise risk oversight duties to committees, but overall risk management, including legal, regulatory, cybersecurity, privacy, and product safety, remains a key area of focus.
• The company operates in a highly regulated business across 95 markets, exposing it to various regulatory compliance risks.
• Des Walsh, a director nominee, has pledged 200,000 Common Shares as collateral to secure personal indebtedness, which could pose a risk if not managed appropriately.

Future Outlook

The company plans to expand Pro2col beta access to additional international markets in 2026, beginning with select EMEA markets, as part of a phased, insight-driven global rollout strategy. Herbalife also intends to refresh its environmental targets in compliance with global environmental regulations. The next shareholder advisory vote on executive compensation is expected at the 2027 annual general meeting, and a new employment agreement with Mr. DeSimone may be entered into upon the expiration of his current CFO Employment Agreement in March 2026.

Management Comments

• "Through our ongoing shareholder engagement efforts, we received meaningful feedback that informed the Compensation Committee's design of the executive compensation program. We view this dialogue with our shareholders as central to aligning our executive compensation plan with Company performance and long-term shareholder value." Maria Otero, Chair, Compensation Committee
• "We are proud of the leadership team's efforts and the Company's performance in 2025, delivering improved results while advancing key strategic initiatives that position the Company to drive long-term shareholder value." Maria Otero, Chair, Compensation Committee
• "Based on evolving business conditions, the Committee reintroduced PSUs in 2025 as a central component of the long-term incentive program." Maria Otero, Chair, Compensation Committee
• "The Committee believes these enhancements strengthen alignment between executive compensation and long-term shareholder value." Maria Otero, Chair, Compensation Committee

Industry Context

StockSavvy.ai notes that Herbalife's strategic focus on expanding its digital wellness platform (Pro2col) and precision nutrition capabilities (Link Bioscience) aligns with broader industry trends towards personalized health solutions and digital engagement in the health and wellness sector. The significant investment from Cristiano Ronaldo further validates the company's strategy in leveraging influencer marketing and brand partnerships, a common tactic in consumer-facing industries. The reintroduction of Performance Share Units (PSUs) in executive compensation reflects a proactive response to shareholder feedback, a trend seen across many public companies aiming to enhance corporate governance and align executive incentives with long-term shareholder value.

Comparison to Industry Standards

• Herbalife's peer group for executive compensation includes 16 companies in consumer product-related industries, such as BellRing Brands, The Campbell's Company, Church & Dwight Co., Inc., and The Clorox Company.
• As of December 31, 2025, Herbalife's trailing twelve-month revenue of $5,038 million placed it at the 45th percentile within its peer group, while its market capitalization of $1,332 million was at the 32nd percentile.
• The company's executive compensation structure, with 73% to 88% of targeted direct compensation tied to performance-based incentives, is designed to be competitive with the pay practices of these peer companies.
• The upside limitation of 120% for Performance Share Unit (PSU) payouts, compared to a market standard of 200%, was implemented to minimize shareholder dilution, indicating a more conservative approach than some industry peers.

Management Changes

Corporate Governance

Related Party Transactions

• Rodica Macadrai and Juan Miguel Mendoza, both directors, earned income as top independent distributors of Herbalife products in 2025, totaling $1,139,317 for Ms. Macadrai and $714,329 for Mr. Mendoza (plus $37,500 for speaking engagements), unrelated to their board service.
• Mr. Mendoza's sister and brother-in-law earned approximately $1,263,466 in 2025 under Herbalife's Marketing Plan as Herbalife Members.
• Stephan Gratziani, Chief Executive Officer, was paid approximately $753,994 in 2025 in consideration for suspending his distributorship operations.
• The company reimbursed Michael O. Johnson, Executive Chairman, $475,457 in 2025 for chartered air transportation services from BLADE Urban Air Mobility, Inc., where his son-in-law serves as a senior executive and aircraft broker. This transaction was reviewed and approved by the Audit Committee.

Stakeholder Impact

• Shareholders: Directly impacted by proposals for director elections, executive compensation, and auditor ratification. Potential for increased value through financial performance, debt reduction, strategic growth initiatives, and the Cristiano Ronaldo investment. Dilution concerns are addressed by RCU implementation and PSU payout caps.
• Employees: Benefit from a competitive executive compensation program designed to attract, motivate, and retain talent. Participation in 401(k) plan, Senior Executive Deferred Compensation Plan, and Employee Stock Purchase Plan, along with life insurance and perquisites.
• Customers/Herbalife Members: Benefit from product innovation (e.g., MultiBurn, Life I/O Baseline, H/L Skin), digital platform expansion (Pro2col), and precision nutrition capabilities (Link Bioscience). Distributor growth and engagement programs aim to strengthen the network.
• Suppliers: The Responsible Sourcing program aims to embed respect for people and the environment in procurements.
• Creditors: Debt reduction of approximately $283 million and a lower total leverage ratio of 2.8x at year-end 2025 improve the company's creditworthiness.
• Communities: The Herbalife Family Foundation awarded approximately $5 million in grants to 165 nonprofit organizations across 60 countries in 2025, supporting nutrition and childhood development initiatives.

Next Steps

• Hold the 2026 Annual General Meeting of Shareholders on April 30, 2026.
• Expand Pro2col beta access to additional international markets in 2026, starting with select EMEA markets, as part of a phased global rollout strategy.
• Refresh environmental targets in compliance with global environmental regulations.
• Conduct the next shareholder advisory vote on executive compensation at the 2027 annual general meeting.
• Potentially enter into a new employment agreement with Mr. DeSimone upon the expiration of his current CFO Employment Agreement (term through March 26, 2026).

Key Dates

Recommendation

Herbalife's 2025 performance shows modest net sales growth and improved Adjusted EBITDA, coupled with strategic acquisitions and a notable investment from Cristiano Ronaldo, which are positive indicators. However, the slight miss on local currency net sales targets and the ongoing need to address shareholder feedback on executive compensation suggest areas for continued focus. The stock's current valuation and the mixed performance against targets warrant a 'hold' recommendation, advising investors to monitor the execution of strategic initiatives and sustained financial improvements before making further investment decisions.

Keywords

Herbalife, Proxy Statement, Annual General Meeting, Corporate Governance, Executive Compensation, Director Election, Financial Performance, Net Sales, Adjusted EBITDA, Debt Reduction, Strategic Acquisitions, Pro2col, Link Bioscience, Pruvit, Cristiano Ronaldo, Sustainability, Risk Management, Shareholder Vote, Direct Selling, Nutrition, Wellness, Health Products